Patients whose asthma is not well controlled by inhaled corticosteroids may benefit from the addition of a long-acting beta 2 agonist. The effects of inhaling a corticosteroid and a long-acting beta 2 agonist can reduce symptoms, improve lung function and prevent exacerbations. Once the patient's asthma is controlled it may be appropriate for them to use one of the combination inhalers which contain both types of drug. These combination inhalers may not be more efficacious than inhaling the drugs separately, but they are more convenient.
Introduction
Combination inhalers that include both a corticosteroid and a long-acting beta 2 The rationale for the use of combination therapy 1 Asthma is a chronic inflammatory condition of the airways in which the predominant inflammatory cells are eosinophils.
Inhaled preparations of corticosteroids have become the standard treatment for asthma as these cells are sensitive to their effects. 1, 2 The airway inflammation also produces increased reactivity in bronchial smooth muscle, leading to bronchoconstriction.
Stimulation of beta 2 adrenergic receptors on smooth muscle cells causes relaxation of bronchial smooth muscle. Beta 2 agonists are therefore used for quick relief of bronchospasm.
Patients with persistent asthmatic symptoms used to take regular doses of short-acting beta 2 agonists, but there was concern that such regular use may worsen asthma and increase asthma deaths. When long-acting beta 2 agonists were developed, there were similar concerns. However, it is now clear that they are of benefit, although they should not be used without an inhaled corticosteroid to treat asthma. 1, 2 The interaction between corticosteroids and beta 2 
agonists
In addition to bronchial smooth muscle, beta 2 adrenergic receptors are also present on other cells in the airways including mast cells and vascular endothelium. With chronic use of beta 2 agonists, these receptors become down-regulated. However, this can be balanced by the concurrent use of corticosteroids because corticosteroids can interact with the beta 2 receptor gene to increase the production of beta 2 receptors in vitro. 1, 2 Inflammation can desensitise beta 2 receptors, and beta 2 stimulation can inhibit some aspects of inflammation, such as mast cell mediator release, and plasma exudation from postcapillary venules. Both of these effects can be prevented by corticosteroids. In turn, beta 2 agonists can increase the actions of corticosteroids by interacting with glucocorticoid receptors in the nucleus and enhancing their binding to DNA. 1, 2 The appropriate dose of corticosteroids agonists shifts the dose-response curve to the left, so the same benefit is achieved with lower daily doses of the steroid.
Once a patient's asthma is controlled, consideration should be given to reducing the dose of inhaled corticosteroid. Exactly when and how this should be done is not clear as there is insufficient evidence. However, the Global INitiative for Asthma (GINA) guidelines 3 suggest that the patient should be stable for at least three months, and the Australian National Asthma Council guidelines state that dose reduction should be considered after asthma has been stable for 6-12 weeks. 4 Leaving patients on high doses of inhaled corticosteroids can lead to systemic adverse effects, and is not appropriate. Adding a long-acting beta 2 agonist may enable a reduction in the dose of corticosteroid.
Clinical data
There have now been many good quality studies showing that the control of moderate or severe asthma can be improved by adding a long-acting beta 2 
Advantages of combination inhalers
It is more convenient for patients who require two asthma drugs to use one, rather than two, inhalers. Another advantage is that it is not possible to stop the steroid if both drugs are given in a single inhaler. This addresses the concern that patients using two inhalers would be tempted to use just the long-acting beta 2 agonist, as it produces a symptomatic improvement faster than steroids can. There is a cost advantage in using a combination inhaler instead of two separate inhalers and there is the possibility that indirect costs may also be reduced. The patient's asthma may be better controlled with the combination and, as a lower dose of inhaled corticosteroid may be needed, the adverse effects can be minimised.
Potential limitations of combination inhalers
A possible limitation with any combination preparation is the lack of flexibility in dosing. This is not such an issue with combination inhalers as there are six different strengths of the fluticasone/salmeterol products and two of the budesonide/eformoterol products ( Table 1 ). The eformoterol dose can be increased as the dose in these products is below the maximum that can be used, so patients can vary their dose during exacerbations.
Another limitation is that patients may use the inhaler to relieve bronchospasm and get much higher doses of inhaled steroid 
When to use combination inhalers
The Australian National Asthma Council guidelines suggest adding a long-acting beta 2 agonist to inhaled steroids if the patient requires a short-acting beta 2 
Prescribing restrictions on combination therapy
Combination inhalers are a restricted benefit if they are prescribed under the Pharmaceutical Benefits Scheme.
They are restricted to patients who have previously had frequent episodes of asthma while receiving optimal doses of inhaled corticosteroids, or oral corticosteroids, and who have been stabilised on the relevant inhaled corticosteroid used concomitantly with the relevant long-acting beta 2 agonist. 
